Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
ARWR 
Arrowhead Pharmaceuticals Inc (ARWR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/20/2026: ARWR (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
15 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $81.36
1 Year Target Price $81.36
| 7 | Strong Buy |
| 3 | Buy |
| 5 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 8.94B USD | Price to earnings Ratio 40.16 | 1Y Target Price 81.36 |
Price to earnings Ratio 40.16 | 1Y Target Price 81.36 | ||
Volume (30-day avg) 15 | Beta 1.22 | 52 Weeks Range 9.57 - 76.76 | Updated Date 02/19/2026 |
52 Weeks Range 9.57 - 76.76 | Updated Date 02/19/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.59 |
Earnings Date
Report Date 2026-02-10 | When - | Estimate 0.1149 | Actual 0.22 |
Profitability
Profit Margin 18.54% | Operating Margin (TTM) 15.46% |
Management Effectiveness
Return on Assets (TTM) 14.35% | Return on Equity (TTM) 75.5% |
Valuation
Trailing PE 40.16 | Forward PE 111.11 | Enterprise Value 8333010365 | Price to Sales(TTM) 8.2 |
Enterprise Value 8333010365 | Price to Sales(TTM) 8.2 | ||
Enterprise Value to Revenue 7.64 | Enterprise Value to EBITDA 22.52 | Shares Outstanding 140032190 | Shares Floating 121755189 |
Shares Outstanding 140032190 | Shares Floating 121755189 | ||
Percent Insiders 3.8 | Percent Institutions 84.25 |
Upturn AI SWOT
Arrowhead Pharmaceuticals Inc
Company Overview
History and Background
Arrowhead Pharmaceuticals Inc. was founded in 1989 and is a biopharmaceutical company that develops medicines that treat intractable diseases by silencing the genes that cause them. The company's core technology platform is based on RNA interference (RNAi). Significant milestones include the development of its TRiMu2122 platform, which improves the delivery of RNAi therapeutics, and successful clinical trials for various drug candidates. Arrowhead has evolved from a research-focused entity to a clinical-stage company with multiple drug candidates in development across a range of therapeutic areas.
Core Business Areas
- RNAi Therapeutics Development: Arrowhead focuses on developing novel therapeutics using its proprietary RNA interference (RNAi) platform, TRiMu2122. This platform is designed to enable targeted delivery of RNAi molecules to specific cells and tissues, leading to the silencing of disease-causing genes.
- Pipeline Advancement: The company's primary business is advancing its pipeline of drug candidates through preclinical and clinical development. This involves significant investment in research, clinical trials, and regulatory submissions.
Leadership and Structure
Arrowhead Pharmaceuticals Inc. is led by a management team with expertise in drug development, biotechnology, and business operations. The organizational structure is typical for a biotechnology company, with dedicated departments for Research and Development, Clinical Operations, Regulatory Affairs, Manufacturing, and Commercial Operations.
Top Products and Market Share
Key Offerings
- ARO-HSD (Hypophosphatasia): A subcutaneously administered RNAi therapeutic targeting alkaline phosphatase to treat hypophosphatasia. Competitors include various enzyme replacement therapies and gene therapies in development.
- ARO-APOC3 (Hypertriglyceridemia): A subcutaneously administered RNAi therapeutic targeting apolipoprotein C-III for the treatment of hypertriglyceridemia. Competitors include PCSK9 inhibitors, antisense oligonucleotides, and other novel lipid-lowering agents.
- ARO-DUO1 (Duchenne Muscular Dystrophy): A potential treatment for Duchenne muscular dystrophy, targeting specific genetic mutations. This is a highly competitive and developing field with gene therapy and exon-skipping approaches from various companies.
- ARO-ANG3 (Dyslipidemia): An RNAi therapeutic targeting angiopoietin-3 for the treatment of severe dyslipidemias. Competitors include gene therapies and other novel drug modalities aimed at managing lipid levels.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly the RNAi therapeutics sector, is characterized by rapid innovation, significant research and development investment, and a focus on unmet medical needs. The market is driven by advances in genetic medicine and a growing understanding of disease mechanisms at the molecular level. Regulatory pathways are becoming more defined for novel modalities, but clinical success remains challenging.
Positioning
Arrowhead Pharmaceuticals Inc. is positioned as a leader in the development of RNAi-based therapeutics, leveraging its proprietary TRiMu2122 delivery platform. Its competitive advantage lies in its ability to target difficult-to-treat diseases with potentially curative or disease-modifying therapies. The company's platform allows for differentiated approaches to drug development.
Total Addressable Market (TAM)
The TAM for Arrowhead's pipeline is substantial, spanning rare genetic diseases, cardiovascular conditions, and other areas with significant unmet needs. For example, the global market for rare diseases is projected to grow significantly. Arrowhead is positioned to capture a portion of this TAM by developing first-in-class or best-in-class therapies for specific indications within these broad markets.
Upturn SWOT Analysis
Strengths
- Proprietary TRiMu2122 delivery platform for enhanced RNAi efficacy and targeting.
- Strong pipeline of drug candidates in various stages of clinical development.
- Experienced management team with a deep understanding of RNAi technology.
- Strategic partnerships with established pharmaceutical companies.
Weaknesses
- High cost and complexity of developing novel therapeutics.
- Dependence on successful clinical trial outcomes.
- Long development timelines and significant R&D expenditure.
- Potential for unforeseen side effects or toxicity issues.
Opportunities
- Expanding the TRiMu2122 platform to new therapeutic areas.
- Securing additional partnerships and collaborations.
- Addressing unmet medical needs in rare and common diseases.
- Advancements in gene editing and other genetic medicine technologies.
Threats
- Competition from other RNAi companies and alternative therapeutic modalities (e.g., gene therapy, mRNA).
- Stringent regulatory hurdles and approval processes.
- Challenges in manufacturing and scaling up novel therapeutics.
- Reimbursement challenges for high-cost advanced therapies.
Competitors and Market Share
Key Competitors
- Alnylam Pharmaceuticals (ALNY)
- Dicerna Pharmaceuticals (DRNA) - now part of Novo Nordisk
- Ionis Pharmaceuticals (IONS)
Competitive Landscape
Arrowhead competes in the rapidly evolving field of RNAi therapeutics. Its advantages include its proprietary TRiMu2122 platform, which offers differentiated delivery capabilities. However, competitors like Alnylam have a more established commercial presence with approved products. Ionis Pharmaceuticals utilizes an antisense oligonucleotide approach, offering a different but related therapeutic modality.
Growth Trajectory and Initiatives
Historical Growth: Arrowhead Pharmaceuticals Inc. has experienced significant growth in its pipeline over the past decade, moving from early-stage research to multiple clinical-stage programs. This growth has been supported by advancements in its RNAi technology and strategic partnerships.
Future Projections: Future growth is projected to be driven by the successful clinical development and commercialization of its leading drug candidates. Analyst estimates will depend on clinical trial results and market potential for its target indications.
Recent Initiatives: Recent initiatives include the advancement of its key pipeline candidates (e.g., ARO-HSD, ARO-APOC3) into later-stage clinical trials, securing new collaborations and partnerships, and ongoing efforts to optimize its TRiMu2122 delivery platform.
Summary
Arrowhead Pharmaceuticals Inc. is a promising biopharmaceutical company with a strong focus on RNAi therapeutics and a proprietary delivery platform. Its robust pipeline and strategic partnerships are key strengths. However, the inherent risks of drug development, intense competition, and the long road to commercialization present significant challenges. Continued successful clinical trials and regulatory approvals are crucial for its future growth and investor returns.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Arrowhead Pharmaceuticals Inc. Investor Relations
- SEC Filings (10-K, 10-Q)
- Industry Analyst Reports
- Biotechnology News and Publications
Disclaimers:
This JSON output is generated based on publicly available information and should not be considered financial advice. Financial data and market share figures are subject to change and may require verification from official sources. The AI-based rating is a subjective assessment and should not be solely relied upon for investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Arrowhead Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Pasadena, CA, United States | ||
IPO Launch date 1993-06-16 | Chairman, CEO & President Dr. Christopher R. Anzalone Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 711 | Website https://arrowheadpharma.com |
Full time employees 711 | Website https://arrowheadpharma.com | ||
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.